Authors

Latest:

Insights from IMS 2024 on Counseling Patients with Multiple Myeloma about CAR T-cell Therapy and Connecting to Referral Centers

Panelists discuss how community providers can implement strategies and utilize resources to effectively connect patients to referral centers for chimeric antigen receptor T-cell therapy, while addressing how to initiate conversations about the therapy and counsel patients regarding potential adverse events.

Noopur S. Raje, MD, Massachusetts General Hospital Cancer Center

Noopur Suresh Raje, MD, Massachusetts General Hospital

Nooshin Hashemi Sadraei, MD

Latest:

Dr. Hashemi Sadraei Discusses Biomarkers in HPV-Induced Tumors

Nooshin Hashemi Sadraei, MD, assistant professor of medicine, Department of Internal Medicine, University of Cincinnati, discusses biomarkers in HPV-induced tumors, including cervical, anal, and oropharyngeal cancers.

Nora O'Dowd

Latest:

Lymph Nodes Overlooked in Ovarian Cancer Patients

Women with early-stage ovarian cancer were nearly twice as likely to die if they did not have recommended staging biopsies of pelvic and aortic lymph nodes

Norman E. Sharpless, MD

Latest:

Dr. Sharpless on Managing Toxicities With Nivolumab and Ipilimumab in Melanoma

Norman E. Sharpless, MD, professor of Medicine and Genetics, chair, the University of North Carolina (UNC) Lineberger Comprehensive Cancer Center, UNC School of Medicine, discusses how oncologists can best manage toxicities associated with the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for the treatment of patients with melanoma.

Northwell Health

Latest:

Northwell Cancer Institute Unveils $14M Center for Women's Cancer, Creating an Integrated Care Model With Comprehensive Services in One Location

The Northwell Cancer Institute unveiled its Center for Women's Cancer at the R.J. Zuckerberg Cancer Center.

Nour A. Obeidat, PhD

Latest:

Racial/Ethnic and Age Disparities in Chemotherapy Selection for Colorectal Cancer

Studies have evaluated racial/ethnic and age disparities in whether patients receive chemotherapy for nonmetastatic colo-rectal cancer

Oana C. Danciu, MD

Latest:

Dr. Danciu on Prescreening and Identifying Breast Cancer Survivors

Oana C. Danciu, MD, assistant professor of Medicine, Division of Hematology/Oncology, University of Illinois Hospital and Health Sciences System, discusses a study examining a team-based approach to prescreen and identify breast cancer survivors using a survivorship care plan.

OBTN

Latest:

December 2011: Trials in Progress

The Trials in Progress section supploes summaries of ongoing research in a broad range of cancer types.

Ola Landgren, MD, PhD

Latest:

Dr Landgren on the Management of Newly Diagnosed Multiple Myeloma Treatment

C. Ola Landgren, MD, PhD, discusses standard treatment approaches and the advantages of quadruplet regimens in newly diagnosed multiple myeloma.

Ola Landgren, MD, PhD, Memorial Sloan Kettering Cancer Center

Olga Frankfurt, MD

Latest:

Dr. Frankfurt on the Future of AML Treatments

Olga Frankfurt, MD, associate professor of medicine, Feinberg School of Medicine, Northwestern University, discusses the future of acute myeloid leukemia (AML) treatments.

Oliver Dorigo, MD, PhD

Latest:

Dr Dorigo on the Clinical Benefit with Maveropepimut-S in Recurrent Ovarian Cancer

Oliver Dorigo, MD, PhD, discusses the clinical efficacy of maveropepimut-S in patients with recurrent ovarian cancer.

Oliver Dorigo, MD, PhD, Stanford University Medical Center

Oliver Sartor, MD

Latest:

Dr Sartor on Ongoing Prostate Cancer Research

Oliver Sartor, MD, discusses ongoing prostate cancer research, highlighting the importance of considering patient quality of life.

Oliver Waidmann, MD, Goethe-Universitat Frankfurt am Main

Oliver Zill

Latest:

Next-Generation Sequencing Analysis of Circulating Tumor DNA

Oliver Zill, data scientist, Guardant Health, discusses the somatic genomic landscape of over 15,000 patients with advanced-stage cancer from clinical next-generation sequencing analysis of circulating tumor DNA.

Oliver Zivanovic, MD, Dennis S. Chi, MD

Latest:

HIPEC for Ovarian Cancer: An Exciting Locoregional Strategy

Approximately 22,000 women will be diagnosed with epithelial ovarian cancer (EOC) in the United States in 2014, making it the nation's second most common gynecologic malignancy.1 The cancer, which often presents at an advanced stage, causes more deaths than any other type of gynecologic malignancy.

Olivia Pagani, MD

Latest:

Dr. Pagani Discusses Aromatase Inhibitors for Premenopausal Women with Breast Cancer

Olivia Pagani, MD, Institute of Oncology, Southern Switzerland, discusses the result of a joint analysis of two phase III trials involving a total of 4690 premenopausal women with hormone-receptorâ€“positive (HR+) breast cancer who were treated with the aromatase inhibitor exemestane.